Publicatiedatum
Hyperlink
Naam tijdschrift
Pathobiology
Introduction: The objective of this study is to cross-check and if necessary, adjust registered ICD-O-3 topography and morphology codes with the findings in pathology reports available at the Belgian Cancer Registry (BCR) for glioma patients. Additionally, integration of molecular markers in the pathological diagnosis and concordance with WHO 2016 classification is investigated.
Methods: Since information regarding molecular tests and corresponding conclusions are not available as structured data at population level, a manual screening of all pseudonymized pathology reports available at the BCR for registered glioma patients (2017-2019) was conducted. ICD-O-3 morphology and topography codes from the BCR database (based on information as provided by hospital oncological care programs and pathology labs), were, at tumour level, cross-checked with the data from the pathology reports and, if needed, specified or corrected. Relevant molecular markers (IDH-1/2, 1p19q codeletion, MGMTp) were manually extracted from the pathology reports.
Results: In 95,3% of gliomas, the ICD-O-3 morphology code was correct. Non-specific topography codes were specified in 9,3%, while 3,3% of specific codes were corrected. The IDH status was known in 75,2% of astrocytic tumours. The rate of correct integrated diagnoses varies from 47,6% to 56,4% among different gliomas. MGMTp methylation status is available in 32,2% of glioblastomas.
Conclusion: Both the integration of molecular markers in the conclusion of the pathology reports and the delivery of those reports to the BCR can be improved. The availability of distinct ICD-O-3 codes for each molecularly defined tumour entity within the WHO classification would increase the consistency of cancer registration, facilitate population level research and international benchmarking.
Methods: Since information regarding molecular tests and corresponding conclusions are not available as structured data at population level, a manual screening of all pseudonymized pathology reports available at the BCR for registered glioma patients (2017-2019) was conducted. ICD-O-3 morphology and topography codes from the BCR database (based on information as provided by hospital oncological care programs and pathology labs), were, at tumour level, cross-checked with the data from the pathology reports and, if needed, specified or corrected. Relevant molecular markers (IDH-1/2, 1p19q codeletion, MGMTp) were manually extracted from the pathology reports.
Results: In 95,3% of gliomas, the ICD-O-3 morphology code was correct. Non-specific topography codes were specified in 9,3%, while 3,3% of specific codes were corrected. The IDH status was known in 75,2% of astrocytic tumours. The rate of correct integrated diagnoses varies from 47,6% to 56,4% among different gliomas. MGMTp methylation status is available in 32,2% of glioblastomas.
Conclusion: Both the integration of molecular markers in the conclusion of the pathology reports and the delivery of those reports to the BCR can be improved. The availability of distinct ICD-O-3 codes for each molecularly defined tumour entity within the WHO classification would increase the consistency of cancer registration, facilitate population level research and international benchmarking.